SCHEMBL4554040

SCHEMBL4554040

CC(=O)c1nc(C(O)C(O)C(O)CO)c[nH]1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.32
PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL306015 1.00 L3MBTL1 (0.32) L3MBTL1PDE4A
SCHEMBL4439438 1.00 L3MBTL1 (0.32) L3MBTL1PDE4A
Water SCHEMBL15482324 0.98 L3MBTL1 (0.31) L3MBTL1
SCHEMBL27044970 0.87 PNP (0.31)
SCHEMBL13372164 0.85 L3MBTL1 (0.32) L3MBTL1
Lx-2931 SCHEMBL304964 0.82 L3MBTL1 (0.33) L3MBTL1
Lx-2931 SCHEMBL20744226 0.82 L3MBTL1 (0.33) L3MBTL1
Lx-2931 SCHEMBL304963 0.82 L3MBTL1 (0.33) L3MBTL1
Lx-2931 SCHEMBL316870 0.82 L3MBTL1 (0.33) L3MBTL1
Lx-2931 SCHEMBL20744228 0.82 L3MBTL1 (0.33) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668506-B1 ENHANCEMENT OF CANCER TREATMENT EFFICIENCY VIA THE SPHINGOSINE-1-PHOSPHATE PATHWAY AC BIOSCIENCE (CH) 2023-12-06 EP claimed
EP-4017844-B1 COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER AC BIOSCIENCE SA (CH) 2024-01-24 EP disclosed
CN-115058468-B Schizophyllan compound polysaccharide, ion-reduced transdermal toning lotion and preparation method thereof 宁波泉水生物科技有限公司 2023-04-28 CN disclosed
US-20220306587-A1 COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER AC BIOSCIENCE SA (CH) 2022-09-29 US disclosed
CN-115058468-A Schizophyllin compound polysaccharide, ion reduction transdermal toning lotion and preparation method thereof 宁波泉水生物科技有限公司 2022-09-16 CN disclosed
CN-114555567-A Compounds and their use for the treatment of infectious diseases and cancer AC生命科学有限公司 2022-05-27 CN disclosed
EP-3286301-B1 GENERATION OF MUSCLE-LINEAGE CELLS FROM STEM CELLS SONIC MASTER LTD (VG) 2021-07-28 EP disclosed
EP-2090334-B1 Imidazole based compounds, compositions comprising them and methods of their use LEXICON PHARMACEUTICALS INC (US) 2015-04-29 EP disclosed
CN-102648185-A Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone LEXICON PHARMACEUTICALS INC 2012-08-22 CN disclosed
EP-2090334-A2 Imidazole based compounds, compositions comprising them and methods of their use Lexicon Pharmaceuticals, Inc. (US) 2009-08-19 EP disclosed
US-20080248032-A1 Using 2-acetyl-4-tetrahydroxybutylimidazole (THI) as therapeutic in treatment and prevention of heart and stroke injury CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) 2008-10-09 US disclosed
US-20080248032-A1 Using 2-acetyl-4-tetrahydroxybutylimidazole (THI) as therapeutic in treatment and prevention of heart and stroke injury CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306587-A1 COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER SGPL1, SPHK1, S1PR1 L3MBTL1 256/4885PDE4A 1103/4885
US-20080248032-A1 Using 2-acetyl-4-tetrahydroxybutylimidazole (THI) as therapeutic in treatment and prevention of heart and stroke injury SPHK1, SPHK2, SPTLC1 L3MBTL1 268/4885PDE4A 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.